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Natural or acquired drug resistance of tumor cells 
is one of the reasons of failure of existing methods of 
cancer treatment. Drug resistance could be mediated, 
in particular, by the altered expression of cytoplasmic 
membrane proteins, which bind chemotherapeutic 
drugs [1, 2].
Within the population of the same tumor, cancer 
cells are heterogenous in various aspects including 
those inherent for drug resistance. Even in tumors 
susceptible to specific cancer treatment, the strong 
selection in the setting of the chemotherapeutic drugs 
is a driving factor of the development of the resistant 
clones and the acquisition of the resistance by the 
tumor as a whole. The altered expression of such onco-
genes as c-fos, c-mys, H-ras, Her/neu, c-jun, c-abl as 
well as р53 tumor suppressor gene is a decisive factor 
in formation of resistance to cisplatin (CP) [3, 4]. The 
study of cell lines derived from stomach cancer resis-
tant to CP, 5-fluorouracil or doxorubicin also identified 
the altered expression of more than 250 genes [5]. The 
changes in activities of several proteolytic enzymes in 
resistant variants of different tumors cells lines was 
demonstrated both in vitro [6, 7], and in vivo [8, 9]. 
Serine proteinases involved in apoptosis are among 
the known factors associated with mechanisms of 
drug resistance formation [6, 8, 10]. Another important 
structure mediating drug resistance in cancer cells is 
P-glycoprotein [11–13].
Recently, the data have been accumulated sug-
gesting various mechanisms of susceptibility of cancer 
cells to the chemotherapeutic drugs as well as cytotoxic 
factors of antitumor immunity [14, 15]. Several reports 
suggest the possibility of designing anticancer vaccines 
based on the active components isolated from the cells 
with drug resistance phenotype [16]. In experimental re-
sistant tumors (intestinal cancer CT-26 and Lewis lung 
carcinoma) hyperexpressing МDR1, the positive effect 
of vaccine based on DNA encoding for МDR1 transfec-
ted to the attenuated strain of Salmonella typhimurium 
turns has been demonstrated [13]. New prospects are 
opened with the advent of dendritic cell technology for 
vaccine production [17, 18].
It is known that drug resistant cancer cells may be 
still susceptible to the effects of the activated autologic 
lymphocytes [15, 17, 19, 20]. However, the data on 
ATV efficacy against the tumors with drug resistance 
phenotype are still insufficient. Therefore, it is of in-
terest to compare the effects of ATV prepared from 
the components of drug-susceptible and resistant 
cancer cells.
Earlier, the development of ATV from CP resistant 
Lewis lung carcinoma (LLC) cells using the cytotoxic 
lectine (CL) of B. subtilis B-7025 have been repor-
ted [21]. The aim of the present study was to compare 
antitumor and antimetastatic activities of ATV prepared 
from the initial and chemoresistant LLC variants in 
therapeutic setting of vaccine administration. The 
parameters characterizing activity of antitumor mac-
rophages were studied in parallel with the analysis of 
the effects on the proteolitic activity in blood plasma 
of experimental animals.
MATERIALS AND METHODS
Adult male C57Bl mice (aged 2.5 months) bred in 
animal facility of R.E. Kavetsky Institute of Experimental 
Pathology, Oncology and Radiobiology were used for 
the experiments. All experiments were performed ac-
cording to the regulations of Ethic Committee of the In-
stitute. Cisplatin resistant (CR) LLC strain was originated 
from the initial LLC strain by the consecutive series of the 
transplantations in the setting of CP injections [9].
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ATV from cisplatin sensitive (CS) LLC and CR 
LCC cells were prepared using cytotoxic lectin (CL) 
of В. subtilis В-7025 according to our method [22]. 
Protein concentration in ATV was 4.0 mg/ml. The ef-
ficacy of ATV was assessed in the therapeutic setting of 
experiment (Table 1). The effects of ATV were evalua-
ted by tumor incidence, life-span of tumor-bearing 
animals, the size of the primary tumor, the number 
and the volume of the metastatic foci.
Table 1. Experimental design
Test Group No. n
Tumor Vaccination
LLC 
variant
Route of 
inoculation 
and dose 
of cells
Origin 
of vaccine Dose Day
І 1 20 CS 4.5 х 105  
in femoral 
muscle
CP sensitive 
LLC
0.3 ml, 
subcuta-
neously
1, 4, 7, 11, 
14
2 20 CP resistant 
LLC
3 20 – – –
4 20 CR 4.5 х 105 
in femoral 
muscle
CP sensitive 
LLC
0.3 ml, 
subcuta-
neously
1, 4, 7, 11, 
14
5 20 CP resistant 
LLC
6 20 – – –
ІІ 1 10 CR 5.0 х 105 
in femoral 
muscle
CP sensitive 
LLC
0.3 ml, 
subcuta-
neously
1, 4, 7, 11, 
14
2 10 CP resistant 
LLC
3 10 – – –
Notes: CS — cisplatin sensitive; CR — cisplatin resistant.
The antitumor activity of cytotoxic T lymphocytes 
(CTL) and natural killer cells (NK cells) was estimated 
by radiometric method [23].
The functional (metabolic) activity of peritoneal 
macrophages (Mph) was assayed by NBT-test [24]. 
The content of tumor necrosis factor (TNF) in culture 
supernatant and blood serum was estimated using 
TNF-sensitive L-929 cells [25]. The total blood plasma 
proteolytic activity (PA) was evaluated by digestion of 
protamine sulfate according to the K.M. Veremeenko 
spectrophotometric method [26].
RESULTS AND DISCUSSION
Mean survival time (MST) of tumor-bearing mice 
was shown to increase upon immunization with ATV 
prepared from either CP sensitive or CP resistant vari-
ant of LLC (Table 2). MST of animals with CP sensitive 
LLC was increased significantly upon administration 
of homologous ATV (prepared from CP sensitive LLC) 
(53.85 ± 4.03 vs 37.5 ± 1.07 days in untreated ani-
mals, р < 0.05), while the effect of ATV prepared from 
CP resistant LLC was not significant. MST of animals 
with CP resistant LLC was increased significantly upon 
admi nistration of ATV prepared either from CP resistant 
or sensitive variant of LLC (see Table 2).
Table 2. MST of mice with CS or CR LLC treated with ATV prepared from 
CS or CR LLC
Tumor Treatment n MST, days M ± m t ILS,%
CS LLC Vaccine from CS LLC 8 53.85 ± 4.03 2.80* +43.6
Vaccine from CR LLC 9 45.15 ± 4.4 1.63 +20.4
– 7 37.50 ± 1.07
CR LLC Vaccine from CS LLC 9 53.71 ± 4.24 3.12* +39.1
Vaccine from CR LLC 7 55.86 ± 5.09 2.95* +44.6
– 38.62 ± 1.39
Notes: CL of B. subtilis B-7025 was used for vaccine preparation. CS — 
cisplatin sensitive; CR — cisplatin resistant; *р < 0.05 in comparison with 
corresponding values in untreated animals.
ATV prepared from CP sensitive LLC decreased the 
final incidence rate of transplanted CS LLC by 30.7% 
and CR LLC only by 15.4%. In mice with transplanted 
CR LLC, ATV prepared from CR LLC decreased the 
final incidence rate of CR tumors by 42.9% and CS 
LLC by 21.4%. These data suggest that ATV prepared 
from homologous LCC strains (sensitive or resistant) 
are more effective.
When the growth inhibition was assessed, ATV 
prepared from CP sensitive LLC inhibited the growth 
of CP sensitive and CP resistant tumors by 24.14% 
and 34.62%, respectively. ATV prepared from CP re-
sistant LLC inhibited the growth of CP sensitive and CP 
resistant tumors by 16.32% and 51.64%, respectively. 
Therefore, ATV prepared from CP resistant LLC inhi-
bited the growth of the homologous LLC (p < 0.05) and 
did not affect significantly the growth of CP sensitive 
LLC strain (p > 0.05).
The functional activity of the effectors mediating 
antitumor response was assayed on the 34th day since 
LLC transplantation, i. e. on the terminal stage of tumor 
growth. According to our previous data as well the data 
of other researchers [27, 28], at that time the immu-
nity of the animals is in the state of exhaustion due to 
inhibition of antitumor immunity partially because of 
immune suppression.
As shown in Table 3, the functional characteristics 
of immune response of vaccinated animals to some 
extend depended on the type of ATV used. Neverthe-
less, in all cases, Mph activity was increased signifi-
cantly. On 34th day of tumor growth in mice with initial 
LLC strain tumors after treatment with ATV based on 
CP sensitive and CP resistant LLC Mph activities were 
respectively 3.2 and 4.7 times more (p < 0.05) than 
in untreated animals. In mice with CP resistant LLC, 
the Mph activities upon treatment with ATV prepared 
from CP resistant LLC were increased 2.1-folds as 
compared with that in untreated animals (p < 0.05). In 
this group only the trend of increasing of NK cell and 
CTL activity was shown (0.05 < p < 0.1).
Table 3. Activity of cell immunity effectors tumor-bearing hosts treated 
with ATV prepared from CS or CR LLC (CL of B. subtilis B-7025 was used 
for vaccine preparation)
Tumor Treatment Cytotoxicity index,%NK cells Mph CTL
CS LLC – 10.0 ± 8.1 15.4 ± 5.98 19.3 ± 5.4
Vaccine from 
CS LLC
13.8 ± 4.8 49.4 ± 11.8* 18.2 ± 2.9
Vaccine from 
CR LLC
28.6 ± 1.6* 71.9 ± 5.9* 13.5 ± 3.5
CR LLC – 18.2 ± 8.1 22.6 ± 6.5 20.3 ± 5.0
Vaccine from 
CS LLC
17.4 ± 12.9 43.6 ± 8.2* 11.7 ± 5.9
Vaccine from 
CR LLC
25.0 ± 7.9 47.1 ± 9.4* 30.6 ± 5.9
Notes: The cytotoxicity was assessed on Day 34 post inoculation. CS — 
cisplatin sensitive; CR — cisplatin resistant; *р < 0.05 in comparison with 
corresponding values in untreated animals.
We attempted to assess whether such Mph activa-
tion is associated with increasing TNF content in the 
supernatants (Sn) of Mph cultures. In Mph cultures of 
intact mice, TNF titer was 2.0 ± 0.2 log2 and cytotoxicity 
index (CI) assayed at 1:2 dilution was 34.6 ± 5.8%. On 
34th day of tumor growth in untreated animals, these 
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indices were 1.3 ± 0.2 log2 and 21.0 ± 1.8% for CP sensi-
tive LLC and 1.5 ± 0.2 log2 and 24.3 ± 1.8% for CP re-
sistant LLC. In ATN-treated animals, the corresponding 
indices were significantly higher than in intact animals 
and tumor-bearing untreated animals (Table 4).
Table 4. Patterns of nonspecific immunity upon treatment with vaccines 
prepared from CS or CR LLC
Group NBT-test of Mph, in absorbance unit
TNF activity 
titer log2
CI, %
Vaccine from CR LLC 0.361 ± 0.0041, 2 4.5 ± 0.11, 2, 3 102.7 ± 15.01, 2, 3
Vaccine from CS LLC 0.383 ± 0.0091 2.3 ± 0.2 48.9 ± 6.5
Untreated mice 
inoculated with LLC
0.397 ± 0.0021 2.6 ± 0.3 56.1 ± 10.5
Intact control 0.476 ± 0.003 2.8 ± 0.2 62.8 ± 10.6
1p < 0.05 in comparison with intact control; 2p < 0.05 in comparison with 
untreated inoculated mice; 3p < 0.05 in comparison with other vaccine 
treatment.
The results of the assay of PA in plasma of the 
experimental animals are presented on Figure as 
percentage relative to control values in untreated 
animals inoculated with LLC taken as 100%. In plasma 
of mice inoculated with CP sensitive LLC and treated 
with homologous vaccine, the trend of decreasing PA 
was observed (0.05 < p < 0.1). On the contrary, PA in 
plasma of animals inoculated with CP resistant LLC was 
increased significantly upon administration of either 
vaccine (from CP resistant or sensitive LLC) (p < 0.05). 
It is suggested that the response of proteolysis system 
to immunotherapy depended on the susceptibility of 
tumor to CP rather than the type of ATV.
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Figure. PA in blood plasma of vaccinated mice with initial and 
CP resistant LLC strain
CP is known to reduce PA in blood of cancer 
patients [29]. The same decrease was observed in 
present study in the animals inoculated with CP sensi-
tive LLC treated with vaccine from CP sensitive LLC. 
On the contrary, PA in plasma of animals inoculated 
with CP resistant LLC was increased upon vaccine 
administration. Such effect may be associated with the 
activation of the effector cells mediating antitumor im-
munity, Mph in particular, which are one of the sources 
providing the increased proteinase level in the blood 
[30]. This fact is in line with the findings demonstrating 
the activation of non-specific immunity in the vaccine-
treated animals inoculated with CP resistant LLC at the 
advanced stages of tumor growth.
There are contradictory data reported by various 
researchers as to the trend of proteolytic enzyme 
activi ty in metastasizing tumors of different histoge-
nesis: both increase [31] and decrease [32] of such 
activity are reported. The views on the effects of pro-
teolytic activity on the survival of cancer cells are also 
quite different [33, 34].
As was shown in our earlier work [8], the forma-
tion of drug resistance phenotype in cancer cells is 
accompanied by the shift on the balance between the 
proteolytic enzymes and their inhibitors towards pro-
teinase activation. PA augmentation associated with 
the formation of drug resistance is associated with the 
increasing metastatic capability of cancer cells.
Therefore, we have analyzed antimetastatic activity 
of the vaccine prepared from CP sensitive or resistant 
LLC in the animals inoculated with CP resistant LLC. 
The antimetastatic efficacy was assessed by the index 
of metastasis inhibition. On the 34th day since inocu-
lation, in treated animals from all groups the size of 
the primary tumor decreased significantly. The ATV 
prepared from CP resistant LLC was more effective (by 
34.4%) than ATV prepared from CP sensitive LLC.
The administration of ATV prepared from either CP 
resistant or sensitive LLC decreased significantly the 
rate of metastasizing as well as the volume of lung 
metastases (Table 5). Index of metastasis inhibition 
(calculated by the relative decrease of the number 
of metastasis as compared to untreated animals) for 
ATV prepared from CP sensitive or resistant LLC was 
154.5% and 227.0%, respectively. The antimetastatic 
effect was most evident when the volume of metasta-
ses was measured (decrease by 87.83% and 83.4% for 
ATV prepared from CP sensitive or resistant LLC).
Table 5. Quantitative characteristics of metastasizing upon inoculation of 
CR LLC in animals treated with ATV prepared from CS or CR LLC
Group Mean lung weight, mg
Mean number 
of metastases
Mean volume of 
metastases, mm3
Vaccine from CR LLC 210.9 ± 11.9* 6.0 ± 2.6* 36.17 ± 21.3*
Vaccine from CS LLC 236.0 ± 22.9 7.71 ± 2.2* 49.48 ± 20.9*
Control 374.2 ± 73.9 19.60 ± 3.1 297.18 ± 79.2
Notes: CS — cisplatin sensitive; CR — cisplatin resistant; *р < 0.05 in 
comparison with corresponding values in untreated animals.
On the 34th day of tumor growth, Mph activity in 
ATV-treated mice measured in NCT-test was the same 
as in untreated mice inoculated with LLC. Neverthe-
less, TNF content in serum of mice treated with ATV 
prepared from CP resistant LLC was 1.7–1.9 times 
higher comparing with all other groups (p < 0.05).
The obtained data demonstrated that ATV from CP 
resistant LLC prepared using cytotoxic lectin (CL) of 
В. subtilis В-7025 significantly inhibited the growth 
of tumors and the development of metastases (by 
52% and 87.83% respectively) with accompanying 
prolongation of MST by 44.6%. Nevertheless, in spite 
of antitumor and antimetastatic effects, the adminis-
tration of such vaccine increased significantly PA in 
plasma of tumor-bearing animals. This phenomenon 
needs further investigations.
The elaborated procedure of administrating ATV 
prepared from CP resistant LLC has been shown to 
activate the effector components of cell-mediated 
immunity in the animals inoculated with CP resistant 
LLC. This is in line with the findings presented N.M. Be-
rezhnaya et al. [14, 19, 20] who demonstrated the 
increased efficacy of several immunotherapeutic mo-
dalities such as vaccine administration or LAC therapy 
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in the animals with resistant tumors (B-16 melanoma, 
MC-rhabdomyosarcoma) as compared to the initial 
strains sensitive to chemotherapy. Moreover, the ex-
plants of human cancers resistant to chemotherapy 
(soft tissue sarcoma, cancer of cervix uteri, ovarian 
cancer) are susceptible to the lysis by the activated 
autologic lymphocytes [15].
While the interpretation of our findings is difficult 
because of the lack of sufficient information on the 
phenomenon of increased susceptibility of chemore-
sistant tumors to the factors of immune response, 
the contribution of cell surface molecules is evident. 
Underlying mechanisms of chemoresistance formation 
are variable. Among them there are epigenetic modifi-
cations of mdr-1 locus and methylation of mdr-1 pro-
moter; activation of enzymes of gluthation system; 
changes of genes and proteins that control apoptosis 
of cancer cells; increased expression of genes coding 
for transmembrane transport proteins (P-glycoprotein) 
etc. [12, 35, 36].
The data on the correlation between the acquisi-
tion of drug resistance and increased susceptibility to 
the effectors of cell-mediated immunity are currently 
limi ted. In particular, Azuma et al. [12] proved the 
presence of cytotoxic T cells specific to MDR-1 in ex-
perimental murine leukemia, but significant correlation 
between P-gp expression and increased sensitivity of 
resistant cancer cells to the factors of immune defense 
has not been yet revealed.
To sum up, the data obtained indicate the impor-
tance of further studies on the mechanisms of the ef-
fects of ATV prepared from chemoresistant tumors with 
the aid of cytotoxic lectin of В. subtilis В-7025. Such 
studies may be advantageous for the improvement of 
the treatment of resistant tumors in clinical setting.
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